Patented Medicine Prices Review Board Will Hear Allegations of Breach of Reporting Requirements for Acne Drugs
(firmenpresse) - OTTAWA, ONTARIO -- (Marketwired) -- 02/25/16 -- Patented Medicine Prices Review Board
The Patented Medicine Prices Review Board (PMPRB) will hold a public hearing with respect to allegations that Galderma Canada Inc. failed to provide the PMPRB with the pricing and sales information required by section 80 of the Patent Act and sections 3 and 4 of the Patented Medicine Regulations. The proceeding relates to the medicines branded as Differin, Differin XP, TactuPump, and TactuPump Forte. These medicines are generally indicated for the treatment of acne.
The purpose of the hearing is to receive evidence and argument of Board Staff, Galderma Canada Inc., and any interveners regarding allegations that Galderma Canada Inc. is in breach of its reporting requirements. The date, time, and location of the public hearing will be set and confirmed at a later date.
Those wishing to participate in this proceeding must apply to the Board for leave to intervene by April 4, 2016. For further information on the application process, please contact:
Quick Facts
Related Products
-
-
Associated Links
- (Justice Canada)
- (Justice Canada)
- (Patented Medicine Prices Review Board)
Contacts:
Sofie McCoy-Astell
Manager, Communications
Patented Medicine Prices Review Board
613-960-9728
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.02.2016 - 15:00 Uhr
Sprache: Deutsch
News-ID 1417842
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
OTTAWA, ONTARIO
Phone:
Kategorie:
National
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 263 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Patented Medicine Prices Review Board Will Hear Allegations of Breach of Reporting Requirements for Acne Drugs
"
steht unter der journalistisch-redaktionellen Verantwortung von
Patented Medicine Prices Review Board (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
